Independent investigation: seven structural drivers behind the US cost premium
Verified per-capita health expenditure from OECD-comparable national accounts. Figures reflect total health spending divided by population, adjusted to USD purchasing-power parity for cross-country comparison.
| Country | Per Capita | % of GDP | vs US | Source |
|---|---|---|---|---|
| United States | $13,432 | 17.6% | Reference | CMS NHE Accounts 2023 · OECD comparable methodology |
| Germany | $8,011 | 12.7% | 40% less | OECD Health Statistics 2024 |
| Canada | $6,319 | 11.2% | 53% less | OECD Health Statistics 2024 |
| United Kingdom | $5,493 | 11.3% | 59% less | OECD Health Statistics 2024 |
| Japan | $4,666 | 11.5% | 65% less | OECD Health Statistics 2024 |
| OECD Average | $5,829 | ~9.2% | 57% less | OECD Health at a Glance 2023 |
Verified 2026-05-20 (CMS National Health Expenditure Accounts 2023; OECD Health Statistics 2024; OECD Health at a Glance 2023). The US gap versus Germany alone — roughly $5,400 per person — multiplied by 330 million Americans, represents a $1.8 trillion structural premium over the next-highest peer spender.
The cost gap is not explained by individual consumer behavior, technological innovation, or sicker patients. It is the cumulative result of seven documented structural drivers, each anchored to peer-reviewed or regulatory sources.
Top 3 PBMs control 79% of US Rx claims (FTC Interim Report 2024). Each layer — insurer, PBM, group purchasing org, third-party administrator — extracts margin without delivering care.
US admin costs run 34% of total health spending vs Canada at 17% (Himmelstein & Woolhandler, AJPH 2020). Matching Canadian efficiency would save roughly $600B per year.
US pays 2.78–4.22× the OECD median on brand drugs (RAND 2024). Insulin lists at $98/vial in the US vs $12 in Canada — same molecule, different pricing system.
Roughly 90% of US metro hospital markets are highly concentrated under DOJ/FTC thresholds (Cooper, Craig, Gaynor, Van Reenen — QJE 2019). Monopoly prices run 12–26% higher than competitive markets, controlling for quality.
Estimated $60–80B per year in tests and procedures ordered primarily to reduce liability risk (Mello, Chandra, Gawande, Studdert — Health Affairs 2010). The cost is embedded in every facility fee.
Only 34.5% of US hospitals comply with the federal Hospital Price Transparency Rule (PatientRightsAdvocate.org 2024). Patients cannot shop on price for procedures where the same MRI bills $200–$3,000 in the same city.
49% of Americans get coverage through employers; family premiums averaged $25,572 in 2024 (KFF Employer Health Benefits Survey). The tax exclusion subsidizes the system that drives admin overhead and locks workers into jobs ('job lock').
If higher spending bought better health outcomes, the US would be at the top of every international ranking. It is not. The Commonwealth Fund's Mirror Mirror 2024 report compares health-system performance across 10 high-income countries on five domains — access, care process, administrative efficiency, equity, and health outcomes. The US ranks last (10 of 10) overall, and last on access, administrative efficiency, equity, and health outcomes individually.
Life expectancy at birth in the US is 77.5 years (CDC 2023 provisional) versus Japan at 84.3 and an OECD average of 80.3. Maternal mortality sits at 22.3 deaths per 100,000 live births — roughly 5× the rate of Germany and Japan (4.0), per OECD Health at a Glance 2023. Avoidable mortality — deaths preventable through timely, effective care — is the highest in the peer group.
The paradox is not about whether US clinicians are skilled or US technology is advanced — both are world-class at the individual level. The system that organizes, finances, and prices that care is what produces the international gap. Every dollar that compounds into the seven structural drivers is a dollar that does not buy better life expectancy, lower maternal mortality, or fewer avoidable deaths.
System-level statistics translate into household-level exposure. 25.3 million Americans were uninsured in 2023 (~7.6% of the population, KFF 2024). Another 43 million are classified as underinsured — meaning out-of-pocket health care costs plus deductibles exceed 10% of household income (Commonwealth Fund Biennial Health Insurance Survey). Together, roughly 70 million Americans operate without the financial protection a health system is supposed to provide.
Medical debt contributes to 66.5% of US bankruptcy filings (Himmelstein, Lawless, Thorne, Foohey, Woolhandler — AJPH 2019). Surprise medical bills averaged $940 per ER visit before the No Surprises Act (2022); compliance with the new framework is ongoing but uneven. Job lock — staying in unwanted employment to keep employer-sponsored coverage — affects an estimated 11–30% of working-age adults depending on the methodology used.
These are not edge cases. They are predictable downstream effects of the seven drivers above — features of the system, not bugs.
Seven structural drivers compound: layered middlemen (the top 3 PBMs control 79% of Rx claims), administrative overhead (34% of spending vs 17% in Canada), brand drug prices (2.78–4.22× the OECD median), hospital consolidation, defensive medicine ($60–80B/yr), price opacity (only 34.5% of hospitals comply with transparency rules), and employer-tied insurance. None of them is 'individual choice.'
About $13,432 per person per year — roughly 2.3× the OECD average — reaching $4.867 trillion, or 17.6% of GDP, in 2023 per CMS National Health Expenditure Accounts. Germany spends $8,011, Canada $6,319, the UK $5,493.
No. The Commonwealth Fund's 2024 Mirror Mirror report ranks the US health system 10th of 10 peer high-income countries on overall performance. US life expectancy is 77.5 years versus 84.3 in Japan and an 80.3 OECD average — highest spending, worst peer outcomes.
About 70 million: 25.3 million uninsured plus 43 million underinsured (KFF 2024), whose out-of-pocket exposure exceeds 10% of household income. Medical debt contributes to 66.5% of US bankruptcies (Himmelstein, AJPH 2019).
Reform is targeting specific layers — Medicare Drug Price Negotiation (IRA 2022, effective 2026), the Hospital Price Transparency Rule, and the No Surprises Act — but the core paradox persists: the US still has the highest spending and among the worst outcomes of peer nations.
All claims in this guide are drawn from publicly available government, intergovernmental, and peer-reviewed academic sources. Direct links below.
Full source list and chapter timestamps appear in the YouTube video description.
Wellness Vision is an independent research platform. We receive zero revenue from clinics, insurers, pharmaceutical companies, PBMs, or referral networks. All claims are verified against publicly available government and peer-reviewed academic sources. Editorial decisions serve patient interests — not commercial ones.
AI-assisted production: Azure Neural TTS Dragon HD Emma2, DALL-E, Grok Imagine. All factual claims human-reviewed against primary sources before publication.
“You shouldn't have to go broke to feel whole.”
